Table 2 Medication histories within six months before conception in the experimental and control groups for each outcome.
From: Risk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy
Hypertensive disorders of pregnancy (required intravenous nicardipine) | Preterm delivery (delivered before 37 weeks of pregnancy) | |||||||
|---|---|---|---|---|---|---|---|---|
Pregnancies, n (%) | Odds ratios (95%CI) | Pregnancies, n (%) | Odds ratios (95%CI) | |||||
Case | Control | Crude | Adjusted | Case | Control | Crude | Adjusted | |
34 (100%) | 263 (100%) | 56 (100%) | 237 (100%) | |||||
Antihypertensive medications within six months before conception | ||||||||
All categories | 9 (26.5%) | 35 (13.3%) | 2.35 (1.01–5.44) | 2.13 a (0.91–5.01) | 15 (26.8%) | 26 (11.0%) | 2.97 (1.45–6.09) | 3.02 b (1.43–6.39) |
Only RASi e | 4 (11.8%) | 28 (10.6%) | 1.30 (0.42–4.02) | 1.27 a (0.41–3.96) | 9 (16.1%) | 21 (8.9%) | 2.21 (0.94–5.16) | 2.17 b (0.88–5.32) |
Medications other than RASi e | 5 (14.7%) | 7 (2.7%) | 6.51 (1.92–22.1) | 5.01 a (1.43–17.5) | 6 (10.7%) | 5 (2.1%) | 6.18 (1.80–21.2) | 6.45 b (1.81–23.0) |
Glucocorticoid therapy within six months before conception | ||||||||
All (DIV or PO) | 4 (11.8%) | 29 (11.0%) | 1.08 (0.35–3.27) | 1.09 c (0.35–3.45) | 6 (10.7%) | 27 (11.4%) | 0.93 (0.37–2.38) | 0.84 d (0.31–2.32) |
DIV e | 1 (2.9%) | 7 (2.7%) | 1.11 (0.13–9.29) | 1.84 c (0.21–16.5) | 1 (1.8%) | 7 (3.0%) | 0.60 (0.07–4.96) | 1.23 d (0.14–10.7) |
PO e | 4 (11.8%) | 28 (10.6%) | 1.12 (0.37–3.41) | 1.14 c (0.36–3.61) | 6 (10.7%) | 26 (11.0%) | 0.97 (0.38–2.49) | 0.87 d (0.31–2.42) |
